Native Human CA199 Protein

CA19-9 (carbohydrate antigen 19-9, also called cancer antigen 19-9 or sialylated Lewis (a) antigen) is a tumor marker that is used primarily in the management of pancreatic cancer. Guidelines from the American Society of Clinical Oncology discourage the use of CA19-9 as a screening test for cancer, particularly pancreatic cancer. The reason is that the test may be falsely normal (false negative) in many cases, or abnormally elevated in people who have no cancer at all (false positive) . The main use of CA19-9 is therefore to see whether a pancreatic tumor is secreting it; if that is the case, then the levels should fall when the tumor is treated, and they may rise again if the disease recurs. CA19-9 can be elevated in many types of gastrointestinal cancer, such as colorectal cancer, esophageal cancer and hepatocellular carcinoma. Apart from cancer, elevated levels may also occur in pancreatitis, cirrhosis, and diseases of the bile ducts. It can be elevated in people with obstruction of the bile ducts.

Cancer Antigen CA19-9, CA 19-9, carbohydrate antigen 19-9, cancer antigen 19-9, sialylated Lewis antigen, Lewis antigen, Sialyl-Lewis A, Lewis a, sialylated Lewis a antigen, CA199, CA19-9, CA 199, CA 19-9

1. Perkins, G.; Slater, E.; Sanders, G.; Prichard, J. (2003) . "Serum tumor markers". American family physician 68 (6) : 1075–1082. 2. Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J, Somerfield M, Hayes D, Bast R (2006) . "ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer". J. Clin. Oncol. 24 (33) : 5313–27. 3. Goonetilleke KS, Siriwardena AK (April 2007) . "Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer". Eur J Surg Oncol 33 (3) : 266–70.